Invitrogen Corp
Article Abstract:
A comparative analysis of the company sales and financial details of Invitrogen Corp. from 1999 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
MedImmune Inc
Article Abstract:
MedImmune Inc. and partner Wyeth who are banking on the success of FluMist, a vaccine, could expect $1 billion in annual sales. With other products doing well as well, an annnual profit growth of 20%-25% out to 2006-2008 can be expected.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Invitrogen Corp
Article Abstract:
Invitrogen Inc. which is leading supplier fo research tools plans to acquire Vertex Pharmaceuticals. Stock is ranked to outpace the market in 2003.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: